Krascendo 1 Trial NCT06497556: Phase 3, Active, not recruiting

Tracking

Comparisons

Automation

Nightly sweep

Loading…

Krascendo 1 Trial NCT06497556: Phase 3, Active, not recruiting | ComplyRx

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer